|
|
Post by kbrion77 on Nov 1, 2016 7:06:38 GMT -5
theweek.com/articles/656203/huge-change-coming-insulin-marketNot one word on Afrezza or Mannkind. But hey they do talk about innovation!!!!! Meanwhile the so-far futile quest continues for what experts say would be a tremendous innovation — an insulin pill. Novo Nordisk, for instance, has such a molecule in early stage trials.
A pill is ground breaking innovation in the insulin world apparently. Seriously I'm trying to keep my head high but MNKD has so far failed in exposure to Afrezza my god.
|
|
|
|
Post by esstan2001 on Nov 1, 2016 7:22:57 GMT -5
theweek.com/articles/656203/huge-change-coming-insulin-marketNot one word on Afrezza or Mannkind. But hey they do talk about innovation!!!!! Meanwhile the so-far futile quest continues for what experts say would be a tremendous innovation — an insulin pill. Novo Nordisk, for instance, has such a molecule in early stage trials.
A pill is ground breaking innovation in the insulin world apparently. Seriously I'm trying to keep my head high but MNKD has so far failed in exposure to Afrezza my god. And didn't they just put their oral insulin program on hold (I thought that was in the article about them cutting diabetes spending and workforce). If I am right, this Rebecca Robins from THE WEEK does real poor journalist research (or I suppose it is possibe the story went to press before the Novo news). |
|
|
|
Post by kbrion77 on Nov 1, 2016 7:28:08 GMT -5
theweek.com/articles/656203/huge-change-coming-insulin-marketNot one word on Afrezza or Mannkind. But hey they do talk about innovation!!!!! Meanwhile the so-far futile quest continues for what experts say would be a tremendous innovation — an insulin pill. Novo Nordisk, for instance, has such a molecule in early stage trials.
A pill is ground breaking innovation in the insulin world apparently. Seriously I'm trying to keep my head high but MNKD has so far failed in exposure to Afrezza my god. And didn't they just put their oral insulin program on hold (I thought that was in the article about them cutting diabetes spending and workforce). If I am right, this Rebecca Robins from THE WEEK does real poor journalist research (or I suppose it is possibe the story went to press before the Novo news). Articles seem to be coming out hand over fist today. It seems like Insulin is going to be taking the same road as EpiPen with national outrage. |
|
|
|
Post by peppy on Nov 1, 2016 8:32:10 GMT -5
 I would want to swear.
it looks like a prison. Someone tell her about afrezza?
Maybe she needs a pump break.
See what your continuous glucose monitor says now?
How do you feel now? How about now?
www.afrezzajustbreathe.com/
|
|
